Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN<sup>®</sup>) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer

Abe,Tomoya; Sagara,Atsunobu; Okada,Daichi; Matsuzaka,Kazumasa

doi:10.3892/mco.2023.2637

Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN^®) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer

Authors:
- Tomoya Abe
- Atsunobu Sagara
- Daichi Okada
- Kazumasa Matsuzaka
View Affiliations

Affiliations: Department of Pharmacy, Saitama Cancer Center, Ina‑machi, Saitama 362‑0806, Japan, Division of Pharmacy Professional Development and Research, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo 142‑8501, Japan
Published online on: March 24, 2023 https://doi.org/10.3892/mco.2023.2637
Article Number: 41
Copyright: © Abe et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study is a safety survey of patients with human epidermal growth factor receptor type 2‑positive, chemotherapy‑naive breast cancer treated with trastuzumab plus paclitaxel at the Saitama Cancer Center (Saitama, Japan) between April 2018 and March 2022. The expression of infusion reaction (IR) and the effect on cardiac function were investigated in patients who switched from reference trastuzumab (HERCEPTIN^®) to biosimilar trastuzumab (Trastuzumab‑NK) and continued treatment (switching group). The two groups (reference vs. biosimilar trastuzumab) had no significant difference in the expression of IR (P>0.999). In the switching group, IR associated with switching did not occur in all nine eligible patients. Left ventricular ejection fraction (LVEF) was used to assess cardiac function, and no patient in either group experienced a significant decrease in LVEF with treatment, meaning that there was no effect of switching on the decrease in LVEF. These results suggested that switching from reference to biosimilar trastuzumab may not have a significant effect on the frequency of IR expression or the occurrence of cardiac dysfunction.

View Figures

View References

1	Esteva FJ, Baranau YV, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, et al: Efficacy and safety of CT-P6 vs. reference trastuzumab in HER2-positive early breast cancer: Updated results of a randomised phase 3 trial. Cancer Chemother Pharmacol. 84:839–847. 2019.PubMed/NCBI View Article : Google Scholar
2	Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, Sharma R, Baczkowski M, Kothekar M, Loganathan S, et al: Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: A randomized clinical trial. JAMA. 317:37–47. 2017.PubMed/NCBI View Article : Google Scholar
3	Pegram MD, Bondarenko I, Zorzetto MMC, Hingmire S, Iwase H, Krivorotko PV, Lee KS, Li RK, Pikiel J, Aggarwal R, et al: PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: A randomised, double-blind study. Br J Cancer. 120:172–182. 2019.PubMed/NCBI View Article : Google Scholar
4	Esteva FJ, Stebbing J, Wood-Horrall RN, Winkle PJ, Lee SY and Lee SJ: A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. Cancer Chemother Pharmacol. 81:505–514. 2018.PubMed/NCBI View Article : Google Scholar
5	Sato K and Kohgo Y: Infusion reactions. Gan To Kagaku Ryoho. 35:1671–1674. 2008.PubMed/NCBI(In Japanese).
6	Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, et al: Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 25:3859–3865. 2007.PubMed/NCBI View Article : Google Scholar
7	Sengupta PP, Northfelt DW, Gentile F, Zamorano JL and Khandheria BK: Trastuzumab-induced cardiotoxicity: Heart failure at the crossroads. Mayo Clin Proc. 83:197–203. 2008.PubMed/NCBI View Article : Google Scholar
8	Kolberg HC, Colleoni M, Demetriou GS, Santi P, Tesch H, Fujiwara Y, Tomasevic Z and Hanes V: Cardiac safety of the trastuzumab biosimilar ABP 980 in Women with HER2-positive early breast cancer in the randomized, double-blind, active-controlled LILAC Study. Drug Saf. 43:233–242. 2020.PubMed/NCBI View Article : Google Scholar
9	Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet. 369:29–36. 2007.PubMed/NCBI View Article : Google Scholar
10	Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–182. 1987.PubMed/NCBI View Article : Google Scholar
11	Li RK, Tokunaga E, Adamchuk H, Vladimirov V, Yanez E, Lee KS, Bondarenko I, Vana A, Hilton F, Ishikawa T, et al: Long-Term Safety and effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in patients with HER2-Positive metastatic breast cancer: Updated results of a randomized, double-blind study. BioDrugs. 36:55–69. 2022.PubMed/NCBI View Article : Google Scholar
12	Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskii D, Pikiel J, et al: CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: A randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol. 18:917–928. 2017.PubMed/NCBI View Article : Google Scholar
13	Tatsuta R, Sumimoto T, Nakahara R, Tanaka R and Itoh H: Comparison of treatment safety between brand-name product and biosimilar of trastuzumab. Gan To Kagaku Ryoho. 48:945–949. 2021.PubMed/NCBI(In Japanese).
14	Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ, Hortobágyi GN and Barnett CM: Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist. 19:228–234. 2014.PubMed/NCBI View Article : Google Scholar
15	Chan AS, Freeswick S and Sklarin NT: Trastuzumab 6 mg/kg and 4 mg/kg can be infused safely over 30 minutes. Cancer Res. 69 (2 suppl)(S3150)2009.
16	Ring A, Simcock R, Mitra S, Bloomfield D, King J, Simpson S, Sadler G and Webb A: Infusion of trastuzumab maintenance doses over 30 minutes. Ann Oncol. 19:1509–1510. 2008.PubMed/NCBI View Article : Google Scholar
17	Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, Kitakaze M, Kinugawa K, Kihara Y, Goto Y, et al: JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure-Digest Version. Circ J. 83:2084–2184. 2019.PubMed/NCBI View Article : Google Scholar
18	Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN and Esteva FJ: Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol. 24:4107–4115. 2006.PubMed/NCBI View Article : Google Scholar
19	Čelutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, Cohen-Solal A, Farmakis D, Tocchetti CG, von Haehling S, et al: Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: A position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 22:1504–1524. 2020.PubMed/NCBI View Article : Google Scholar